ライフサイエンスコーパス: bronchospasm

1 erents to elicit symptoms, such as cough and bronchospasm.

2 rity from mild itching of the oral mucosa to bronchospasm.

3 bradycardia, hypotension, hypoglycemia, and bronchospasm.

4 when activated, lead to ASM contraction and bronchospasm.

5 effects including atrioventricular block and bronchospasm.

6 We recorded no increased risk of bronchospasm.

7 perioperative bradycardia, hypotension, and bronchospasm.

8 d from 18 hrs to 5 days during resolution of bronchospasm.

9 R(1) increased and L and C(2) decreased with bronchospasm.

10 uctive lung disease and profound, refractory bronchospasm.

11 monary disease tolerated tecadenoson without bronchospasm.

12 which may predispose to oxidative injury and bronchospasm.

13 perienced neutropenic fever and one had mild bronchospasm.

14 ild asthma subjected to methacholine-induced bronchospasm.

15 chest pain, AV conduction abnormalities, and bronchospasm.

16 (10.5%), acute laryngeal edema (9%), severe bronchospasm (2.1%), and six fatal cases (1.8%) were rec

17 w-dose ovalbumin (OVA) only produced a small bronchospasm (~2-fold the basal lung resistance), previo

18 ical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in pat

19 The administration of zileuton inhibited bronchospasm after exercise challenge by 40.75% as compa

20 rse events were reported, except a transient bronchospasm after orotracheal intubation in an asthmati

21 f combined smoke inhalation and burn injury, bronchospasm and acute airway obstruction contribute to

22 mitted to an intensive care unit with severe bronchospasm and an upper respiratory tract infection.

23 eta2-blockade risks causing life-threatening bronchospasm and reduced efficacy of beta2-agonist emerg

24 Events like bronchospasm and stiff chest wall were also tested to de

25 er airway obstruction and complications like bronchospasm and stiff chest wall.

26 e presence of IL-11 correlates with clinical bronchospasm and that IL-11 is a potent inducer of airwa

27 truction resulting from airway inflammation, bronchospasm, and mucus plugging.

28 ators in the development of exercise-induced bronchospasm, and that leukotriene inhibit may have a ro

29 y morbidity (e.g., hypotension, bradycardia, bronchospasm, and/or congestive heart failure).

30 ostol and PGE2 effectively blocked the acute bronchospasm caused by a subsequent inhaled antigen chal

31 hoalveolar lavage fluid obtained during this bronchospasm contained increased ATP concentration.

32 eceived cisatracurium exhibited intermittent bronchospasm during and after the study period.

33 those of asthma and that, in the presence of bronchospasm during anesthesia, AS should be considered

34 er a HA was associated with a higher risk of bronchospasm during intra-operative AS.

35 patient with preexisting asthma had an acute bronchospasm during the first cycle and was removed from

36 with diurnal peak expiratory flow variation, bronchospasm following exercise, the need for asthma med

37 The role of ATP in the allergic bronchospasm has been scantly studied.

38 subjects with asthma with hyperpnea-induced bronchospasm (HIB).

39 ve been reports of bradycardia, hypotension, bronchospasm, hypoglycemia, and electrolyte disturbances

40 These results suggest that the mechanisms of bronchospasm in AS may be different from those of asthma

41 ve beta-blockers because it has less risk of bronchospasm in asthmatics and it comes in a transcutane

42 otides and ectonucleotidases in the allergic bronchospasm in guinea pigs.

43 tion represents a novel approach to managing bronchospasm in obstructive lung diseases.

44 oidal anti-inflammatory drugs (NSAIDs) cause bronchospasm in susceptible patients with asthma, often

45 n requiring treatment other than reversal of bronchospasm in the study laboratory.

46 ntrally and synergistically to modify reflex bronchospasm initiated by airway mechanoreceptor stimula

47 nd functional airway problems (laryngospasm, bronchospasm, insufficient depth of anesthesia and muscl

48 Exercise-induced bronchospasm is a common clinical problem that is partic

49 st abscess, n = 1; fatigue, n = 1; and cough/bronchospasms, n = 1).

50 (hypoglycemia, hypotension, bradycardia, and bronchospasm) occurred infrequently, with no significant

51 methacholine bronchoprovocation to mimic the bronchospasm of mild asthma and (2) while breathing on a

52 nonimmediate cutaneous eruptions, and 17 of bronchospasm related to ASA/nonsteroidal anti-inflammato

53 ulmonary complications, including pneumonia, bronchospasm, respiratory failure and prolonged mechanic

54 s with mild asthma with methacholine-induced bronchospasm results in a minor but significant relaxati

55 s are protean (flushing, sweating, diarrhea, bronchospasm), usually misdiagnosed, and reflect secreti

56 ted-receptor-2 (PAR2) results in relief from bronchospasm via airway smooth muscle relaxation.

57 he only factor statistically associated with bronchospasm was a neuromuscular blocking drug, with bot

58 High-grade atrioventricular block and bronchospasm were not observed.

59 or audiometry and no episodes of significant bronchospasm were observed in association with active tr

60 tagonists, which abolished capsaicin-induced bronchospasm, were without effect on baseline cholinergi

61 Nucleotides greatly potentiate the allergic bronchospasm when ectonucleotidases activity is diminish